Celldex Therapeutics (CLDX) Capital Expenditures (2010 - 2026)

Celldex Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 518.49% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 122.17% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, up 41.43% from the prior year.
• Capital Expenditures improved to $1.6 million in Q1 2026 per CLDX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.6 million in Q1 2026 and bottomed at $157000.0 in Q3 2023.
• The 5-year median for Capital Expenditures is $545000.0 (2024), against an average of $583411.8.
• Across the five-year window, Capital Expenditures plunged 54.49% in 2023 and surged 518.49% in 2026, its largest moves.
• Year by year, Capital Expenditures stood at $235000.0 in 2022, then surged by 183.4% to $666000.0 in 2023, then climbed by 13.51% to $756000.0 in 2024, then jumped by 69.44% to $1.3 million in 2025, then climbed by 27.95% to $1.6 million in 2026.
• Per Business Quant, the three latest CLDX Capital Expenditures figures stand at $1.6 million (Q1 2026), $1.3 million (Q4 2025), and $440000.0 (Q3 2025).